Nios LongTerm Growth Potential Possibility of Doubling by 2029 Bitcoin Dips Below 76K as Geopolitical Risks and ETF Outflows Weigh on Sentiment B2Gold Corp BTG Strengthens Balance Sheet by Selling Interest in Fingold Ventures AutoZone Shares Slide Sharply Despite Earnings Beat Marking Steepest Decline in Four Years Astrana Health ASTH Q1 Earnings Review Outperformance Among Healthcare Technology for Providers Stocks Stellantis Restructuring Prediction Market Oversight Oura IPO Headline Morning Market Movers EWBC Q1 2026 Earnings EPS Surpasses Estimates Amid Solid Operating Performance V Q1 2026 Earnings Earnings Beat Estimates Stock Slightly Soft SLMBP Q1 2026 Earnings Strong EPS Surprise Drives Investor Attention Acadia Healthcare Q1 2026 Earnings Strong EPS Surprise Amid Operational Focus CHT Q1 2026 Earnings EPS Misses Estimates Stock Declines Marginally CTAS Q1 2026 Earnings EPS Misses Estimates Stock Sees Modest Gain LeMaitre Vascular Inc LMAT Holds Steady Near 98 as Traders Await Catalyst The Marzetti Company MZTI Edges Lower Amid Tight Trading Range Rekor Systems REKR Slips Slightly as Stock Consolidates Near Key Support Level Axsome Therapeutics AXSM Slips Slightly While Holding Key Support Levels Renatus Tactical Acquisition Corp I Unit RTACU Hovers Near Key Support Amid Quiet Trading New Found Gold Corp Among LowPriced Gold Stocks Attracting Investor Attention AGNC Q1 2026 Earnings EPS Surges Past Estimates as Stock Gains Ground MasterCraft Boat Holdings MCFT Holds Steady Near Support as Traders Eye Resistance APA Corporation APA Q1 2026 Earnings EPS Surges Past Estimates But Stock Declines Amidst Mixed Signals CLS Q1 2026 Earnings Beat and Raise as Celestica Delivers Strong EPS Surprise Calidi Biotherapeutics Q4 2025 Earnings Narrowed Loss Per Share Exceeds Expectations Despite Stock Decline NSA Q1 2026 Earnings EPS Surpasses Estimates Amid Modest Stock Decline STKS Q1 2026 Earnings EPS Misses Estimates by Wide Margin Amid Operational Headwinds DEFSEC Technologies Q2 2024 Earnings EPS Miss Weighs on Results as Stock Gains Despite Weakness ELDN Q1 2026 Earnings ClinicalStage Biotech Misses EPS Estimates Amid Ongoing Development Costs